Images List Premium Download Classic

Leukemia

Leukemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Method for mass producing natural killer cell and use of natural killer cell obtained by ...
Korea Research Institute Of Bioscience And Biotechnology
January 18, 2018 - N°20180015123

The present invention relates to a method for producing a large amount of natural killer cells and the use of natural killer cells obtained by the method as an anticancer agent. The use of the method of the present invention can produce fresh nk cells with high purity within a short time compared to conventional method, and can also produce ...
Methods of selecting and isolating cancer stem cells
The Regents Of The University Of California
January 11, 2018 - N°20180011100

Provided herein are methods for selecting/identifying and/or isolating cancer stem cells from a biological sample or a cell culture sample using a fluorescent glucose analog. Also provided herein are methods for selecting/identifying and/or isolating leukemia stem cells and subpopulations thereof. The present invention is based, in part, on the discovery that cancer stem cells can be ...
Leukemia methylation markers and uses thereof
The Regents Of The University Of California
January 11, 2018 - N°20180010192

Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of immunomodulatory effective kits for the immunotherapeutic treatment of patients suffering from myeloid leukemias
Cellectis
January 11, 2018 - N°20180008674

The present invention relates to a method for selecting an immunomodulatory kit, selected for an individual patient, for use in the treatment of patients suffering from myeloid leukemias. Different kits are available for selection and ex vivo testing which are composed of substances that have different immunomodulatory effects on leukemia cells. Each kit particularly contains gm-csf and one (or two) ...
Combination methods for treating cancers
Cellectis
January 11, 2018 - N°20180008608

Or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is ...
Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same
Medpacto Inc.
January 11, 2018 - N°20180008579

Provided are a pharmaceutical composition for preventing or treating chronic myeloid leukemia and a method of preventing or treating chronic myeloid leukemia using the same, thereby being effectively applied to the prevention or treatment of chronic myeloid leukemia.
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof
Cantargia Ab
January 04, 2018 - N°20180002430

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (il1rap) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘can04’ to human il1rap. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/...
Cll1-specific multi-chain chimeric antigen receptor
Cellectis
January 04, 2018 - N°20180002427

The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars, which are made specific to the antigen cll1. Such cars aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen cll1. The alpha, beta and gamma polypeptides composing these cars are designed to assemble in juxtamembrane position, ...
Cd33 specific chimeric antigen receptors
Intrexon Corporation
January 04, 2018 - N°20180002397

Provided herein are chimeric antigen receptors (cars) for cancer therapy, and more particularly, cars containing a scfv from a cd33 monoclonal antibody. Provided are immune effector cells containing such cars, and methods of treating proliferative disorders such as acute myeloid leukemia (aml), and relapsed or refractory aml.
Glut-1 as a receptor for htlv envelopes and its uses
Universite Montpellier Ii
January 04, 2018 - N°20180002383

The present application relates to a method for diagnosing a glucose transporter type 1 (glut1) deficiency syndrome that utilizes polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of primate t-cell leukemia virus (ptlv). The polypeptides, named receptor binding domain ligands (rbd), are selected for their ability to bind specifically to glut1. The method involves determining the ...
Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
Cellectis
January 04, 2018 - N°20180000914

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from an anti-hsp70 monoclonal antibody, conferring specific immunity against hsp70 positive cells. The engineered immune cells endowed with such cars are particularly ...
Biomarkers for predicting responsiveness to decitabine therapy
The Regents Of The University Of Michigan
December 28, 2017 - N°20170368091

Provided herein is technology relating to predicting a subject's resistance or responsiveness to a decitabine based therapy and particularly, but not exclusively, to methods, compositions, and related uses for predicting a subject's resistance or responsiveness to a decitabine based therapy wherein the subject is diagnosed with chronic myelomonocytic leukemia.
Use of 4-(4-fluoro-2-methoxyphenyl)-n--1,3,5-triazin-2-amine for treating leukemias
Bayer Pharma Aktiengesellschaft
December 28, 2017 - N°20170368069

The present invention relates to the use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound a), more particularly (+)-4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound a′), for treating leukemias, in particular acute leukemias, preferably acute myeloid leukemias.
Leukemia Patent Pack
Download 157+ patent application PDFs
Leukemia Patent Applications
Download 157+ Leukemia-related PDFs
For professional research & prior art discovery
inventor
  • 157+ full patent PDF documents of Leukemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4...
Sunesis Pharmaceuticals, Inc.
December 28, 2017 - N°20170368041

Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of sns-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering sns-595 in combination with cytarabine. Pharmaceutical ...
Method of treatment of philadelphia chromosome positive leukemia
Csl Limited
December 21, 2017 - N°20170362328

The invention provides a method for the treatment of ph+ leukemia in a patient comprising administering to the patient (i) a bcr-abl tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of ...
Melampomagnolide b dimers
Bioventures, Llc
December 21, 2017 - N°20170362254

The present disclosure provides dimers of melampomagnolide b (mmb), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of mmb. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (aml). A compound comprising formula (1) wherein: z is independently selected from the group consisting of ch2, o, c(o), and ch, wherein ...
Polypeptide and polypeptide complex for suppressing tumor metastasis and treating leukemia as well as preparation ...
Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences
December 21, 2017 - N°20170360897

The present invention provides a group of polypeptides and a complex formed by the polypeptides and human serum albumin, a method for improving the solubility of the group of polypeptides in a salt solution by combining the polypeptides with human serum albumin, a method for preparing the complex formed by the group of polypeptides and human serum albumin, and an ...
Activin-actrii antagonists and uses for treating anemia
Acceleron Pharma Inc.
December 21, 2017 - N°20170360887

Provided herein are methods for the treatment in a subject of anemia, anemia requiring rbc transfusion, low or intermediate-1-risk myelodysplastic syndromes (mds), and/or non-proliferative chronic myelomonocytic leukemia (cmml) in any mammals wherein the methods comprise administration of activin-actrii signaling inhibitors to a subject in need of the treatment.
Pharmaceutical composition comprising bicyclic nitrogen-containing aromatic heterocyclic amide compound as active ingredient
Acceleron Pharma Inc.
December 21, 2017 - N°20170360781

[means for solution] as a result of intensive examination for creating a pharmaceutical composition for treating various types of cancer, the inventors of the present invention confirmed that a specific bicyclic nitrogen-containing aromatic heterocyclic amide compound has the effect of inhibiting mitochondrial complex i and activating ampk, and that a pharmaceutical composition comprising the compound as an active ingredient has ...
2,3-dihydro-1h-indole compounds
Eli Lilly And Company
December 14, 2017 - N°20170354641

The present invention relates to certain novel 2,3-dihydro-1h-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, ...
Monitoring health and disease status using clonotype profiles
Adaptive Biotechnologies Corp.
December 07, 2017 - N°20170349954

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to ...
Loading